| dc.description.abstract | Background and purpose: Morphine-CR and oxycodone-CR is a opioid in oral
form to treat cancer pain. Currently, Curenty oxycodone-CR has just been
available in Indonesia. This study aims to prove the difference of VAS value on
the use of Morphin-CR 30 mg oral and Oxyodone-CR 20 mg oral in cancer pain.
Methods: Double blinded randomized controlled trial that compares the effect of
oral morphine-CR with oral oxycodone-CR as analgesia for cancer pain. Patients
who had fulfilled the inclusion and exclusion criterias were divided into 2 groups
(n: 22), morphine-CR group with 30mg/12hours and the oxycodone-CR group
with 20mg/12hours oral dose, were added paracetamol 1000 mg every 6 hours.
Pain scale assessment (VAS) performed in 4 hours, 12 hours, 24 hours and 48
hours of monitoring. Statistical test used paired T test before treatment and
independent T test after treatment in both group.
Results: Homogeneous subject characteristic data and VAS data in both groups
were not normally distributed. VAS values in each group of CR-morphine group
and CR-oxycodone group were not significantly different between before drug
administration with 4 hours, 12 hours, 24 hours and 48 hours after first drug
administration. There was no significant difference between CR-morphine group
and CR-oxycodone group after 4 hours, 12 hours, 24 hours and 48 hours after
drug administration (p> 0.05).
Conclusion: Morphine-CR 30 mg oral and oxycodone-CR 20 mg oral
significantly decreased the VAS values in cancer patients with severe pain. | en_US |
